Search
Kyverna became the first company this month to initiate a BLA for CAR-T to treat an autoimmune condition. CEO Warner Biddle describes Stiff Person Syndrome and what it means as PoC
He discusses the data from the registrational trial that was presented at AAN last month, and the timeline of the BLA. Plus, myasthenia gravis, which is already in a pivotal, and other conditions the company is considering.
May 20
Checking in on the progress of CAR-T for autoimmune conditions with the CEO of Kyverna - the company's first (and first for the field) registration intended trial will read in the first half of 2026
Warner Biddle describes the trajectory of the field, and how neuro-autoimmune conditions have emerged as Kyverna's most advanced...
Aug 13, 2025
.png){kind=logo}